The findings of a randomized phase III trial reveal similar levels of efficacy of 20 mg/m2 or 25 mg/m2 cabazitaxel, or 75 mg/m2 docetaxel (all regimens included prednisone) in men with metastatic castration-resistant prostate cancer (mCRPC). Patients in each group had median overall survival durations of 24.5, 25.2, and 24.3 months, respectively. Patients receiving 25 mg/m2 cabazitaxel had the highest radiographic tumour response rate, but also the greatest incidence of grade 3–4 adverse events, including febrile neutropenia, diarrhoea and haematuria. These findings reveal similar efficacy of either approach, albeit with differing risks of adverse events.
References
Oudard, S. et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J. Clin Oncol. http://dx.doi.org/10.1200/JCO.2016.72.1068 (2017).
Rights and permissions
About this article
Cite this article
Sidaway, P. Chemotherapy outcomes similar in mCRPC. Nat Rev Clin Oncol 14, 586 (2017). https://doi.org/10.1038/nrclinonc.2017.134
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.134